One-Step Solid Extraction for Simultaneous Determination of Eleven Commonly Used Anticancer Drugs and One Active Metabolite in Human Plasma by HPLC-MS/MS by Shouhong Gao, Zhengbo Tao, Jingya Zhou, Zhipeng Wang, Yunlei Yun, Mingming Li, Feng Zhang, Wansheng Chen, Yejun Miao

“…A liquid chromatography-tandem mass spectrometry method had been developed and fully validated for simultaneous determination of paclitaxel, docetaxel, vinblastine, vinorelbine, pemetrexed, carboplatin, etoposide, cyclophosphamide, ifosfamide, gemcitabine, irinotecan, and SN-38 (an active metabolite of irinotecan) in human plasma from cancer patients after intravenous drip of chemotherapy drugs. One-step solid-phase extraction was successfully applied using an Ostro sample preparation 96-well plate for plasma samples pretreated with acetonitrile containing 0.1% formic acid. …”
Get full text

Therapeutic Implications of PPARγ in Human Osteosarcoma by Eric R. Wagner, Bai-Cheng He, Liang Chen, Guo-Wei Zuo, Wenli Zhang, Qiong Shi, Qing Luo, Xiaoji Luo, Bo Liu, Jinyong Luo, Farbod Rastegar, Connie J. He, Yawen Hu, Barrett Boody, Hue H. Luu, Tong-Chuan He, Zhong-Liang Deng, Rex C. Haydon

“…Current OS management involves chemotherapy and surgery. Peroxisome proliferator-activated receptor (PPAR) agonists and/or retinoids can inhibit OS proliferation and induce apoptosis and may inhibit OS growth by promoting osteoblastic terminal differentiation. …”
Get full text

Oxaliplatin-Loaded Chitosan Nanoparticles Decorated with Cetuximab Single-Chain Variable Fragment for Human Colorectal Cancer Treatment by Khadijeh Falahzadeh, Fariba Esmaeili, Leila Nematollahi, Elham Bayat, Mehdi Khoobi, Mohammadali Mazloomi, Masumeh Jalalvand, Reza Faridi Majidi, Babak Negahdari

“…This delivery system offers a promising method for delivering chemotherapy drugs to cancer cells. Moreresearch is needed on the best strategies for improving treatment efficacy by targeting cancer cells.…”
Get full text

An Optimized Liquid Chromatography–Mass Spectrometry Method for Ganglioside Analysis in Cell Lines by Akeem Sanni, Andrew I. Bennett, Yifan Huang, Isabella Gidi, Moyinoluwa Adeniyi, Judith Nwaiwu, Min H. Kang, Michelle E. Keyel, ChongFeng Gao, C. Patrick Reynolds, Brian Haab, Yehia Mechref

“…Neuroblastoma, a pediatric cancer of the sympathetic nervous system, is treated with intensive chemotherapy, radiation, and an antibody targeting the GD2 ganglioside. …”
Get full text

Neuroendocrine Neoplasms of the Gallbladder: A Clinicopathological Analysis of 13 Patients and a Review of the Literature by Pengyan Wang, Jingci Chen, Ying Jiang, Congwei Jia, Junyi Pang, Shan Wang, Xiaoyan Chang

“…Kaplan-Meier’s analysis demonstrated that liver metastasis and TNM stage III-IV were associated with decreased OS (P<0.05), whereas age, sex, tumor size, grade of the neuroendocrine component, lymph node metastasis, and adjuvant chemotherapy were not significantly prognostic indicators of OS. …”
Get full text

Trends in survival of patients with stage I/II Burkitt lymphoma in the United States: A SEER database analysis by Ze‐Long Liu, Pan‐Pan Liu, Xi‐Wen Bi, De‐Xin Lei, Yu Wang, Zhi‐Ming Li, Wen‐Qi Jiang, Yi Xia

“…The time period was divided into two eras (1983‐2001 and 2002‐2014) as the recent era reflected more intensive chemotherapy regimens, the availability of rituximab, the widespread use of antiretroviral therapy (ART) and improvements in supportive care. …”
Get full text

GPR137-RAB8A activation promotes ovarian cancer development via the Hedgehog pathway by Chao Tang, Lin Li, Chongying Zhu, Qiang Xu, Zihao An, Shouying Xu, Chao Lin

“…While treatments in clinic includes primary surgery and targeted chemotherapy, curative and survival trends in OC have not significantly improved. …”
Get full text

Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report by Oliver Illini, Anna Sophie Lang-Stöberl, Hannah Fabikan, Christoph Weinlinger, Arschang Valipour, Maximilian J. Hochmair

“…Results: All patients were diagnosed with a metastatic adenocarcinoma, had previously progressed on at least one line of chemotherapy and had been previously treated with trastuzumab-deruxtecan (two had to stop treatment because of pneumonitis). …”
Get full text

Analysis of mutations in CDC27, CTBP2, HYDIN and KMT5A genes in carotid paragangliomas by E. N. Lukyanova, A. V. Snezhkina, D. V. Kalinin, A. V. Pokrovsky, A. L. Golovyuk, O. A. Stepanov, E. A. Pudova, G. S. Razmakhaev, M. V. Orlova, A. P. Polyakov, M. V. Kiseleva, A. D. Kaprin, A. V. Kudryavtseva

“…Surgical treatment remains high-risk and extremely challenging; radiation and chemotherapy are poorly effective. The study of molecular pathogenesis of CPGLs will allow developing novel therapeutic approaches and revealing biomarkers. …”
Get full text

miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting by Yilan Xu, Danyang Li, Na Wang, Bei Ge, Chen Meng, Min Zhao, Zihan Lin, Min Li, Yigang Yuan, Yue Cai, Liuzhi Shi, Shenmeng Gao, Haige Ye

“…Abstract Background 5-Azacytidine (AZA) combined with the BCL2 inhibitor Venetoclax (VEN) is the standard treatment for elderly acute myeloid leukemia (AML) patients or those who are unfit for intensive chemotherapy (elderly or unfit AML). However, an effective and rapid predictive biomarker to predict treatment outcome remains elusive. …”
Get full text

The economic burden of breast cancer in western Iran: a cross-sectional cost-of-illness study by Banafsheh Darvishi Teli, Meysam Behzadifar, Mania Beiranvand, Aziz Rezapour, Seyed Jafar Ehsanzadeh, Samad Azari, Ahad Bakhtiari, Payam Haghighatfard, Mariano Martini, Maryam Saran, Masoud Behzadifar

“…Direct medical costs comprised 70.2% of the total expenses, primarily attributed to hospitalization, chemotherapy, and laboratory tests. Direct non-medical costs, including accommodation and transportation for patients and their companions, accounted for 12.5%. …”
Get full text

Gastrointestinal Bleeding due to Pancreatic Disease-Related Portal Hypertension by Kexin Zheng, Xiaozhong Guo, Ji Feng, Zhaohui Bai, Xiaodong Shao, Fangfang Yi, Yongguo Zhang, Rui Zhang, Han Liu, Fernando Gomes Romeiro, Xingshun Qi

“…Three elderly patients (>60 years old) were diagnosed with pancreatic cancer, of whom one underwent laparoscopic radical distal pancreatectomy and splenectomy, one received chemotherapy, and another one chose conservative management due to multiple systemic metastases. …”
Get full text

Exploring the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms and its potential diagnostic value by L. Yin, R. Wang, X. Ma, K. Jiang, Y. Hu, X. Zhao, L. Zhang, Z. Wang, T. Long, M. Lu, J. Li, Y. Sun

“…DLL3 expression rates were 54.8% in GEP-NECs at the primary site, associated with small cell neuroendocrine carcinoma (SCNEC) (p < 0.001), chemotherapy before baseline (p = 0.015), and at least two NE markers (p = 0.048). …”
Get full text

The value of MRI in differentiating ovarian clear cell carcinoma from other adnexal masses with O-RADS MRI scores of 4–5 by Lingling Lin, Le Fu, Huawei Wu, Saiming Cheng, Guangquan Chen, Lei Chen, Jun Zhu, Yu Wang, Jiejun Cheng

“…Critical relevance statement CCC has a high incidence rate in Asians and has limited sensitivity to platinum chemotherapy. This comprehensive model improves CCC prediction ability and clinical applicability for facilitating individualised clinical decision-making. …”
Get full text

Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary Perspective by Yeh Chen Lee, Nazlin Jivraj, Catherine O’Brien, Tanya Chawla, Eran Shlomovitz, Sarah Buchanan, Jenny Lau, Jennifer Croke, Johane P. Allard, Preeti Dhar, Stephane Laframboise, Sarah E. Ferguson, Neesha Dhani, Marcus Butler, Pamela Ng, Terri Stuart-McEwan, Pamela Savage, Lisa Tinker, Amit M. Oza, Stephanie Lheureux

“…This review summarizes the current literature on the different approaches targeting MBO management including surgical intervention, chemotherapy, total parenteral nutrition, and pharmacological treatment. …”
Get full text

Early tolerance and late persistence as alternative drug responses in cancer by Simona Punzi, Davide Cittaro, Guido Gatti, Gemma Crupi, Oronza A. Botrugno, Antonino Alex Cartalemi, Alon Gutfreund, Caterina Oneto, Valentina Giansanti, Chiara Battistini, Giovanni Santacatterina, Lucrezia Patruno, Ilaria Villanti, Martina Palumbo, Daniel J. Laverty, Francesca Giannese, Alex Graudenzi, Giulio Caravagna, Marco Antoniotti, Zachary Nagel, Ugo Cavallaro, Luisa Lanfrancone, Timothy A. Yap, Giulio Draetta, Nathalie Balaban, Giovanni Tonon

“…Here, we show that human cancer cells elicit a tolerant response when exposed to commonly used chemotherapy regimens, propelled by the pervasive activation of autophagy, leading to the comprehensive activation of DNA damage repair pathways. …”
Get full text

Pretransplant immunotherapy increases acute rejection yet improves survival outcome of HCC patients with MVI post-liver transplantation by Xinjun Lu, Qi Zhu, Junfeng Cai, Zuozhong Yang, Guangxiang Gu, Li Pang, Mingye Su, Fapeng Zhang, Haoming Lin, Wenrui Wu, Leibo Xu, Chao Liu

“…However, no synergistic anti-tumor effects were observed with pretransplant ICI immunotherapy when combined with locoregional of TACE, HAIC, RFA and systematic of lenvatinib or sorafenib downstaging treatments, nor with post-transplant adjuvant of systematic or FOLFOX chemotherapy. Further comprehensive studies are needed to balance the dual natural effects of immunotherapy by optimizing downstaging protocols and patient selection to reduce acute rejection and improve long-term survival.…”
Get full text

Associations Between Patient-Reported Nutritional Status, Toxicity, and Survival in Limited-Stage SCLC by Evgenia Taranova, Marianne Aanerud, MD, PhD, Tarje O. Halvorsen, MD, PhD, Kristin T. Killingberg, MD, PhD, Marit Slaaen, MD, PhD, Bjørn H. Grønberg, MD, PhD

“…Methods: Patients received platinum-etoposide-chemotherapy and were randomized to receive TRT of 60 Gy in 40 fractions or 45 Gy in 30 fractions. …”
Get full text

Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis by Jeff Clarke, Xiaofei Wang, Thomas Stinchcombe, Scott J Antonia, Jeffrey Crawford, Neal Ready, Konstantin H Dragnev, Lin Gu, Cameron Wood, James M Isaacs, Liliana Lyniv, Kent Weinhold, Jacob M Kaufman, Eziafa I Oduah, Betty C Tong, Dennis Wigle

“…Patients received two doses of 200 mg pembrolizumab, surgery, standard adjuvant chemotherapy, followed by four doses adjuvant pembrolizumab. …”
Get full text

Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design by Haiying Qin, Nirali N Shah, Terry J Fry, Lila Yang, John A Chukinas, Samiksha Tarun, Marie Pouzolles, Christopher D Chien, Lisa M Niswander, Anthony R Welch, Sarah K Tasian, Naomi A Taylor

“…Background Successful development of chimeric antigen receptor (CAR) T cell immunotherapy for children and adults with relapsed/refractory acute myeloid leukemia (AML) is highly desired given their poor clinical prognosis and frequent inability to achieve cure with conventional chemotherapy. Initial experiences with CD19 CAR T cell immunotherapy for patients with B-cell malignancies highlighted the critical impact of intracellular costimulatory domain selection (CD28 vs 4-1BB (CD137)) on CAR T cell expansion and in vivo persistence that may impact clinical outcomes. …”
Get full text